Trinity Biotech pays $12m for US diabetes testing firm Primus:
This article was originally published in Clinica
Trinity Biotech, of Dublin, Ireland, has entered the diabetes testing market through the $12m acquisition of Primus, a Kansas City, Missouri-based firm that makes glycohaemoglobin testing instruments and reagents. Primus reported sales of $7.9m in 2004, and holds an estimated 35% share of the US variant A1c testing market. It expects US FDA approval for a new point-of-care rapid gel HbA1c product early next year. Nasdaq-listed Trinity will pay up to an additional $4.6m to Primus shareholders depending on continuing business growth in 2005.
You may also be interested in...
Dr Reddy’s sees its Indian domestic market and China as hot prospects as it pursues its “transformation journey” in which it is reducing its dependence on the slowing US market.
Glenmark has struck a deal with private equity firm True North for its gynecology business in India and Nepal.